Analysts Anticipate Editas Medicine Inc (EDIT) Will Announce Earnings of -$0.72 Per Share

Equities research analysts expect Editas Medicine Inc (NASDAQ:EDIT) to post ($0.72) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Editas Medicine’s earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.91). Editas Medicine reported earnings of ($0.64) per share in the same quarter last year, which would suggest a negative year over year growth rate of 12.5%. The business is expected to announce its next quarterly earnings report on Tuesday, November 6th.

On average, analysts expect that Editas Medicine will report full-year earnings of ($3.00) per share for the current financial year, with EPS estimates ranging from ($3.32) to ($2.55). For the next financial year, analysts expect that the business will report earnings of ($3.36) per share, with EPS estimates ranging from ($4.26) to ($2.90). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that cover Editas Medicine.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Monday, August 6th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.15). Editas Medicine had a negative net margin of 623.35% and a negative return on equity of 61.27%. The firm had revenue of $7.37 million for the quarter, compared to the consensus estimate of $7.01 million. During the same period in the previous year, the company posted ($0.65) earnings per share. Editas Medicine’s quarterly revenue was up 137.7% on a year-over-year basis.

EDIT has been the subject of a number of research reports. BidaskClub lowered Editas Medicine from a “hold” rating to a “sell” rating in a research note on Wednesday, August 8th. Raymond James initiated coverage on Editas Medicine in a research note on Friday, September 21st. They set an “outperform” rating and a $40.00 price target for the company. Zacks Investment Research lowered Editas Medicine from a “buy” rating to a “hold” rating in a research note on Thursday, August 9th. Guggenheim initiated coverage on Editas Medicine in a research note on Tuesday. They set a “neutral” rating for the company. Finally, JPMorgan Chase & Co. set a $36.00 price target on Editas Medicine and gave the company a “hold” rating in a research note on Monday, August 6th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $46.50.

In other news, CFO Andrew A. F. Hack sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $32.23, for a total value of $322,300.00. Following the completion of the sale, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at approximately $322,300. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Vickesh Myer sold 14,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 18th. The shares were sold at an average price of $35.63, for a total value of $498,820.00. Following the completion of the sale, the insider now directly owns 3,000 shares of the company’s stock, valued at $106,890. The disclosure for this sale can be found here. Insiders sold a total of 86,333 shares of company stock valued at $2,751,900 over the last ninety days. Corporate insiders own 5.20% of the company’s stock.

Large investors have recently bought and sold shares of the company. Asset Dedication LLC lifted its stake in shares of Editas Medicine by 4,400.0% in the 2nd quarter. Asset Dedication LLC now owns 4,500 shares of the company’s stock valued at $161,000 after purchasing an additional 4,400 shares during the last quarter. Reynders McVeigh Capital Management LLC purchased a new stake in shares of Editas Medicine in the second quarter worth approximately $202,000. Telos Capital Management Inc. purchased a new stake in shares of Editas Medicine in the second quarter worth approximately $203,000. Element Capital Management LLC purchased a new stake in shares of Editas Medicine in the first quarter worth approximately $201,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Editas Medicine in the first quarter worth approximately $207,000. 67.18% of the stock is owned by institutional investors and hedge funds.

Shares of Editas Medicine stock opened at $27.32 on Wednesday. Editas Medicine has a 12 month low of $20.29 and a 12 month high of $45.02. The company has a market cap of $1.52 billion, a P/E ratio of -9.17 and a beta of 3.37. The company has a debt-to-equity ratio of 0.14, a current ratio of 14.50 and a quick ratio of 14.50.

Editas Medicine Company Profile

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

Featured Story: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply